Outcomes of liver transplantation for nonalcoholic steatohepatitis: A systematic review and meta-analysis

Clinical Gastroenterology and Hepatology

Volumn 12, Issue 3, 2014, Pages

  Wang, Xiaofei ^a   Li, Jingdong ^a,b   Riaz, D R ^a   Shi, Gang ^a   Liu, Chongqing ^a   Dai, Yi ^a  

^a AFFILIATED HOSPITAL OF NORTH SICHUAN MEDICAL COLLEGE   (China)

^b CHINESE PLA GENERAL HOSPITAL   (China)

Author keywords

Liver Transplantation; Meta analysis; Nonalcoholic Steatohepatitis

Indexed keywords

ARTICLE; CARDIOVASCULAR DISEASE; CARDIOVASCULAR MORTALITY; COCHRANE LIBRARY; EMBASE; GRAFT FAILURE; HUMAN; LIVER TRANSPLANTATION; MEDLINE; META ANALYSIS; NONALCOHOLIC FATTY LIVER; OUTCOME ASSESSMENT; POSTOPERATIVE COMPLICATION; RISK ASSESSMENT; SENSITIVITY ANALYSIS; SEPSIS; SURGICAL MORTALITY; SURVIVAL RATE; SURVIVAL TIME; SYSTEMATIC REVIEW;

LIVER TRANSPLANTATION; META-ANALYSIS; NONALCOHOLIC STEATOHEPATITIS;

CARDIOVASCULAR DISEASES; FATTY LIVER; HUMANS; LIVER TRANSPLANTATION; SEPSIS; SURVIVAL ANALYSIS; TREATMENT OUTCOME;

EID: 84893953781     PISSN: 15423565     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cgh.2013.09.023     Document Type: Article

References (36)

1. Saadeh S., Younossi Z.M. The spectrum of nonalcoholic fatty liver disease: from steatosis to nonalcoholic steatohepatitis. Cleve Clin J Med 2000, 67:96-97. 101-104.
2. Neuschwander-Tetri B.A., Caldwell S.H. Nonalcoholic steatohepatitis: summary of an AASLD Single Topic Conference. Hepatology 2003, 37:1202-1219.
3. Bacon B.R., Farahvash M.J., Janney C.G., et al. Nonalcoholic steatohepatitis: an expanded clinical entity. Gastroenterology 1994, 107:1103-1109.
4. Angulo P. Nonalcoholic fatty liver disease. NEngl J Med 2002, 346:1221-1231.
5. Bugianesi E., Leone N., Vanni E., et al. Expanding the natural history of nonalcoholic steatohepatitis: from cryptogenic cirrhosis to hepatocellular carcinoma. Gastroenterology 2002, 123:134-140.
6. White D.L., Kanwal F., El-Serag H.B. Association between nonalcoholic fatty liver disease and risk for hepatocellular cancer, based on systematic review. Clin Gastroenterol Hepatol 2012, 10:1342-1359.
7. Torres D.M., Williams C.D., Harrison S.A. Features, diagnosis, and treatment of nonalcoholic fatty liver disease. Clin Gastroenterol Hepatol 2012, 10:837-858.
8. Koehler E., Watt K., Charlton M. Fatty liver and liver transplantation. Clin Liver Dis 2009, 13:621-630.
9. Charlton M.R., Burns J.M., Pedersen R.A., et al. Frequency and outcomes of liver transplantation for nonalcoholic steatohepatitis in the United States. Gastroenterology 2011, 141:1249-1253.
10. Park C.W., Tsai N.T., Wong L.L. Implications of worse renal dysfunction and medical comorbidities in patients with NASH undergoing liver transplant evaluation: impact on MELD and more. Clin Transplant 2011, 25:E606-E611.
11. Vanwagner L.B., Bhave M., Te H.S., et al. Patients transplanted for nonalcoholic steatohepatitis (NASH) are at increased risk for post-operative cardiovascular events. Hepatology 2012, 56:1741-1750.
12. Houlihan D.D., Armstrong M.J., Davidov Y., et al. Renal function in patients undergoing transplantation for nonalcoholic steatohepatitis cirrhosis: time to reconsider immunosuppression regimens?. Liver Transpl 2011, 17:1292-1298.
13. Reddy S.K., Steel J.L., Chen H.W., et al. Outcomes of curative treatment for hepatocellular cancer in nonalcoholic steatohepatitis versus hepatitis C and alcoholic liver disease. Hepatology 2012, 55:1809-1819.
14. Kennedy C., Redden D., Gray S., et al. Equivalent survival following liver transplantation in patients with non-alcoholic steatohepatitis compared with patients with other liver diseases. HPB (Oxford) 2012, 14:625-634.
15. Bhagat V., Mindikoglu A.L., Nudo C.G., et al. Outcomes of liver transplantation in patients with cirrhosis due to nonalcoholic steatohepatitis versus patients with cirrhosis due to alcoholic liver disease. Liver Transpl 2009, 15:1814-1820.
16. Barritt ASt, Dellon E.S., Kozlowski T., et al. The influence of nonalcoholic fatty liver disease and its associated comorbidities on liver transplant outcomes. JClin Gastroenterol 2011, 45:372-378.
17. Malik S.M., deVera M.E., Fontes P., et al. Outcome after liver transplantation for NASH cirrhosis. Am J Transplant 2009, 9:782-793.
18. Agopian V.G., Kaldas F.M., Hong J.C., et al. Liver transplantation for nonalcoholic steatohepatitis: the new epidemic. Ann Surg 2012, 256:624-633.
19. Afzali A., Berry K., Ioannou G.N. Excellent posttransplant survival for patients with nonalcoholic steatohepatitis in the United States. Liver Transpl 2012, 18:29-37.
20. Wells G, Shea B, O'Connell D, etal. The Newcastle-Ottawa Scale (NOS) for assessing the quality of nonrandomised studies in meta-analyses. Available at: http://www.ohri.ca/programs/clinical_epidemiology/oxford.asp.
21. Demets D.L. Methods for combining randomized clinical trials: strengths and limitations. Stat Med 1987, 6:341-350.
22. DerSimonian R., Laird N. Meta-analysis in clinical trials. Control Clin Trials 1986, 7:177-188.
23. Higgins J.P., Thompson S.G. Quantifying heterogeneity in a meta-analysis. Stat Med 2002, 21:1539-1558.
24. Egger M., Davey Smith G., Schneider M., et al. Bias in meta-analysis detected by a simple, graphical test. BMJ 1997, 315:629-634.
25. Liberati A., Altman D.G., Tetzlaff J., et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate healthcare interventions: explanation and elaboration. BMJ 2009, 339:b2700.
26. Kanwal F., White D. Systematic reviews and meta-analyses. Clin Gastroenterol Hepatol 2012, 10:1184-1186.
27. Cohen J. Coefficient of agreement for nominal scales. Educ Psychol Measure 1960, 20:37-46.
28. Therapondos G., Flapan A.D., Plevris J.N., et al. Cardiac morbidity and mortality related to orthotopic liver transplantation. Liver Transpl 2004, 10:1441-1453.
29. Picardi A., Vespasiani-Gentilucci U. Association between non-alcoholic fatty liver disease and cardiovascular disease: a first message should pass. Am J Gastroenterol 2008, 103:3036-3038.
30. Targher G. Non-alcoholic fatty liver disease, the metabolic syndrome and the risk of cardiovascular disease: the plot thickens. Diabet Med 2007, 24:1-6.
31. Bhatia L.S., Curzen N.P., Byrne C.D. Nonalcoholic fatty liver disease and vascular risk. Curr Opin Cardiol 2012, 27:420-428.
32. Wade J.J., Rolando N., Hayllar K., et al. Bacterial and fungal infections after liver transplantation: an analysis of 284 patients. Hepatology 1995, 21:1328-1336.
33. Al-Hasan M.N., Razonable R.R., Eckel-Passow J.E., et al. Incidence rate and outcome of gram-negative bloodstream infection in solid organ transplant recipients. Am J Transplant 2009, 9:835-843.
34. Caldwell S.H., Oelsner D.H., Iezzoni J.C., et al. Cryptogenic cirrhosis: clinical characterization and risk factors for underlying disease. Hepatology 1999, 29:664-669.
35. Clark J.M., Diehl A.M. Nonalcoholic fatty liver disease: an underrecognized cause of cryptogenic cirrhosis. JAMA 2003, 289:3000-3004.
36. Struben V.M., Hespenheide E.E., Caldwell S.H. Nonalcoholic steatohepatitis and cryptogenic cirrhosis within kindreds. Am JMed 2000, 108:9-13.